News
ImmunOs Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC)
– Preclinical data highlighting mode-of-action of lead program iosH2
ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, today announced that the Company will present a scientific poster at the upcoming Society for Immunotherapy of Cancer 36th Annual Meeting (SITC) which will be held November 10-14, 2021, in Washington, DC, USA.
The poster will feature key preclinical data demonstrating the mode-of-action of ImmunOs Therapeutics´ lead program iosH2. The compound is a first-in-class multi-functional agent that promotes key components of the innate immune system and synergizes with the adaptive immune system, thereby leading to profound anti-tumor activity. A Phase I trial is currently in preparation.
Presentation Details
| Poster Title: | “iosH2 exerts potent anti-tumor activity by blocking LILRB1/2 and KIR3DL1 receptor signaling” |
| Abstract ID: | 865 |
| Category: | Novel Single-Agent Immunotherapies |
| Date: | Friday, Nov. 12, 2021 |
| Time: | 7:00 am – 5:00 pm |
| Location: | Poster Hall at the Walter E. Washington Convention Center |
Accepted abstracts can be found in the Journal for ImmunoTherapy of Cancer (JITC).
In addition, ImmunOs´ Therapeutics COO & CBO Jeffrey Abbey will attend this year´s virtual BIO-Europe 2021 and will be available for one-on-one meetings.
###
About ImmunOs Therapeutics AG
ImmunOs Therapeutics AG focuses on the development of a new class of biologic therapeutics for the treatment of cancer and autoimmune diseases. The Company has established a proprietary R&D platform for the development of HLA-based therapeutics addressing multiple targets via a single fusion protein. Its novel compounds are fully human and modulate the innate immune system, synergizing with the adaptive immune system. ImmunOs Therapeutics´ lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors and activates anti-tumor responses.
ImmunOs Therapeutics AG is supported by top-tier investors including Pfizer Ventures, BioMed Partners, Redalpine, Schroder Adveq, Wille Finance AG, BERNINA BioInvest Ltd and UZH Life Sciences Fund as well as undisclosed private investors.
The Company is a spin-off from the Universities of Zurich and Basel and based in Schlieren, Switzerland.
For more information, please visit www.immunostherapeutics.com